UPDATE: SVB Leerink On Theseus Outperform Initiation: Firm Highlights Co.'s Lead Asset THE-630, Which 'Covers All Known Major Classes Of KIT Activating & Resistance Mutations In GIST'; Notes EGFR Inhibitor Program As Additional Key Value Driver